AU2020294724A1 - Ectonucleotidase inhibitors and methods of use thereof - Google Patents

Info

Publication number

AU2020294724A1

AU2020294724A1 AU2020294724A AU2020294724A AU2020294724A1 AU 2020294724 A1 AU2020294724 A1 AU 2020294724A1 AU 2020294724 A AU2020294724 A AU 2020294724A AU 2020294724 A AU2020294724 A AU 2020294724A AU 2020294724 A1 AU2020294724 A1 AU 2020294724A1

Authority

AU

Australia

Prior art keywords

compound

amino

cancer

purin

chloro

Prior art date

2019-06-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 46
• 239000003112 inhibitor Substances 0.000 title description 13
• 108010047482 ectoATPase Proteins 0.000 title description 4
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
• 201000011510 cancer Diseases 0.000 claims abstract description 36
• 150000001875 compounds Chemical class 0.000 claims description 211
• -1 cyano, azido, amino Chemical group 0.000 claims description 74
• 125000000217 alkyl group Chemical group 0.000 claims description 69
• 125000003118 aryl group Chemical group 0.000 claims description 54
• 125000001072 heteroaryl group Chemical group 0.000 claims description 49
• 125000000623 heterocyclic group Chemical group 0.000 claims description 45
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
• 102100022464 5'-nucleotidase Human genes 0.000 claims description 32
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 31
• 125000001424 substituent group Chemical group 0.000 claims description 31
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 27
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
• 201000010099 disease Diseases 0.000 claims description 22
• 239000002246 antineoplastic agent Substances 0.000 claims description 21
• 229940127089 cytotoxic agent Drugs 0.000 claims description 21
• 125000004475 heteroaralkyl group Chemical group 0.000 claims description 21
• 150000003839 salts Chemical class 0.000 claims description 21
• 239000008194 pharmaceutical composition Substances 0.000 claims description 20
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
• 206010006187 Breast cancer Diseases 0.000 claims description 14
• 125000003342 alkenyl group Chemical group 0.000 claims description 14
• 210000004027 cell Anatomy 0.000 claims description 14
• 208000035475 disorder Diseases 0.000 claims description 14
• 208000026310 Breast neoplasm Diseases 0.000 claims description 13
• 125000003545 alkoxy group Chemical group 0.000 claims description 13
• 125000000304 alkynyl group Chemical group 0.000 claims description 13
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 13
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 12
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 10
• 229960004679 doxorubicin Drugs 0.000 claims description 9
• 206010009944 Colon cancer Diseases 0.000 claims description 8
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
• 206010033128 Ovarian cancer Diseases 0.000 claims description 8
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
• 229940002612 prodrug Drugs 0.000 claims description 8
• 239000000651 prodrug Substances 0.000 claims description 8
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
• 206010038389 Renal cancer Diseases 0.000 claims description 7
• 201000010982 kidney cancer Diseases 0.000 claims description 7
• 201000005202 lung cancer Diseases 0.000 claims description 7
• 208000020816 lung neoplasm Diseases 0.000 claims description 7
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
• 208000012902 Nervous system disease Diseases 0.000 claims description 6
• 208000029742 colonic neoplasm Diseases 0.000 claims description 6
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
• 229940045207 immuno-oncology agent Drugs 0.000 claims description 6
• 239000002584 immunological anticancer agent Substances 0.000 claims description 6
• 201000001441 melanoma Diseases 0.000 claims description 6
• ZHQRPIRGSWEALJ-UHFFFAOYSA-N 1-amino-4-(1-naphthalenylamino)-9,10-dioxo-2-anthracenesulfonic acid Chemical compound C1=CC=C2C(NC3=C4C(=O)C5=CC=CC=C5C(=O)C4=C(C(=C3)S(O)(=O)=O)N)=CC=CC2=C1 ZHQRPIRGSWEALJ-UHFFFAOYSA-N 0.000 claims description 5
• ZCQMYMXRGJWSHH-UHFFFAOYSA-N 1-amino-4-(4-aminoanilino)-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=CC(N)=CC=C1NC1=CC(S(O)(=O)=O)=C(N)C2=C1C(=O)C1=CC=CC=C1C2=O ZCQMYMXRGJWSHH-UHFFFAOYSA-N 0.000 claims description 5
• KFBGXLCLNATBFL-UHFFFAOYSA-N 1-amino-4-(4-hydroxyanilino)-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C(N)=C2C(=O)C3=CC=CC=C3C(=O)C2=C1NC1=CC=C(O)C=C1 KFBGXLCLNATBFL-UHFFFAOYSA-N 0.000 claims description 5
• JXFRJOYKTCEJDG-UHFFFAOYSA-N 1-amino-4-(anthracen-2-ylamino)-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=CC=CC2=CC3=CC(NC4=C5C(=O)C6=CC=CC=C6C(=O)C5=C(C(=C4)S(O)(=O)=O)N)=CC=C3C=C21 JXFRJOYKTCEJDG-UHFFFAOYSA-N 0.000 claims description 5
• OPBOOIFXQHPAPJ-UHFFFAOYSA-N 1-amino-4-anilino-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C(N)=C2C(=O)C3=CC=CC=C3C(=O)C2=C1NC1=CC=CC=C1 OPBOOIFXQHPAPJ-UHFFFAOYSA-N 0.000 claims description 5
• XOSSHQAJIWXWOC-UHFFFAOYSA-N 2,2-dimethyl-n-[(4-sulfamoylphenyl)carbamothioyl]propanamide Chemical compound CC(C)(C)C(=O)NC(=S)NC1=CC=C(S(N)(=O)=O)C=C1 XOSSHQAJIWXWOC-UHFFFAOYSA-N 0.000 claims description 5
• OBFSYBSKXOCXQH-UHFFFAOYSA-N 2-[(4-amino-9,10-dioxo-3-sulfoanthracen-1-yl)amino]-5-fluorobenzoic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC1=CC=C(F)C=C1C(O)=O OBFSYBSKXOCXQH-UHFFFAOYSA-N 0.000 claims description 5
• PNFZSRRRZNXSMF-UHFFFAOYSA-N 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid Chemical compound O=CC1=C(O)C(C)=NC(N=NC=2C(=CC(=CC=2)S(O)(=O)=O)S(O)(=O)=O)=C1COP(O)(O)=O PNFZSRRRZNXSMF-UHFFFAOYSA-N 0.000 claims description 5
• PJBFVWGQFLYWCB-QUYAXPHCSA-N 7805s5hihx Chemical compound C([C@H](C[C@@H](C1)C2)C3)C2C31C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 PJBFVWGQFLYWCB-QUYAXPHCSA-N 0.000 claims description 5
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 5
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 5
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 5
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
• 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
• 206010016654 Fibrosis Diseases 0.000 claims description 5
• 208000025966 Neurological disease Diseases 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 5
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 5
• ZWTVVWUOTJRXKM-UHFFFAOYSA-N Tonapofylline Chemical compound C1CC(CCC(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 ZWTVVWUOTJRXKM-UHFFFAOYSA-N 0.000 claims description 5
• LIKZXCROQGHXTI-UHFFFAOYSA-M acid blue 25 Chemical compound [Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC1=CC=CC=C1 LIKZXCROQGHXTI-UHFFFAOYSA-M 0.000 claims description 5
• 125000003368 amide group Chemical group 0.000 claims description 5
• 229960004117 capecitabine Drugs 0.000 claims description 5
• 230000000747 cardiac effect Effects 0.000 claims description 5
• 229960002436 cladribine Drugs 0.000 claims description 5
• 229960000684 cytarabine Drugs 0.000 claims description 5
• 230000004761 fibrosis Effects 0.000 claims description 5
• 229960000390 fludarabine Drugs 0.000 claims description 5
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 5
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
• 229960005277 gemcitabine Drugs 0.000 claims description 5
• 208000026278 immune system disease Diseases 0.000 claims description 5
• 208000023589 ischemic disease Diseases 0.000 claims description 5
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
• 125000002950 monocyclic group Chemical group 0.000 claims description 5
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
• 235000005875 quercetin Nutrition 0.000 claims description 5
• 229960001285 quercetin Drugs 0.000 claims description 5
• 229950008067 rolofylline Drugs 0.000 claims description 5
• GSBYVRKLPCSLNV-UHFFFAOYSA-M sodium 2,4-dinitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 GSBYVRKLPCSLNV-UHFFFAOYSA-M 0.000 claims description 5
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 5
• 229950009502 tonapofylline Drugs 0.000 claims description 5
• VZPXDCIISFTYOM-UHFFFAOYSA-K trisodium;1-amino-4-[4-[[4-chloro-6-(3-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC(C=C1S([O-])(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S([O-])(=O)=O)=C1 VZPXDCIISFTYOM-UHFFFAOYSA-K 0.000 claims description 5
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
• 208000018737 Parkinson disease Diseases 0.000 claims description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
• 208000015114 central nervous system disease Diseases 0.000 claims description 4
• 230000002490 cerebral effect Effects 0.000 claims description 4
• 201000004101 esophageal cancer Diseases 0.000 claims description 4
• 208000027866 inflammatory disease Diseases 0.000 claims description 4
• 229960004857 mitomycin Drugs 0.000 claims description 4
• 208000019116 sleep disease Diseases 0.000 claims description 4
• 208000008732 thymoma Diseases 0.000 claims description 4
• 229960004066 trametinib Drugs 0.000 claims description 4
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 4
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
• XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 claims description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
• 229960003957 dexamethasone Drugs 0.000 claims description 3
• 229960002949 fluorouracil Drugs 0.000 claims description 3
• 206010017758 gastric cancer Diseases 0.000 claims description 3
• 230000010243 gut motility Effects 0.000 claims description 3
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
• JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims description 3
• 229950004847 navitoclax Drugs 0.000 claims description 3
• 230000000626 neurodegenerative effect Effects 0.000 claims description 3
• 230000000926 neurological effect Effects 0.000 claims description 3
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
• 229960001756 oxaliplatin Drugs 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 229960004641 rituximab Drugs 0.000 claims description 3
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 3
• 229960003452 romidepsin Drugs 0.000 claims description 3
• OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 3
• 108010091666 romidepsin Proteins 0.000 claims description 3
• 201000011549 stomach cancer Diseases 0.000 claims description 3
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 3
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 2
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
• JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
• 102000015790 Asparaginase Human genes 0.000 claims description 2
• 108010024976 Asparaginase Proteins 0.000 claims description 2
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
• 206010005003 Bladder cancer Diseases 0.000 claims description 2
• 108010006654 Bleomycin Proteins 0.000 claims description 2
• 206010005949 Bone cancer Diseases 0.000 claims description 2
• 208000018084 Bone neoplasm Diseases 0.000 claims description 2
• 108010037003 Buserelin Proteins 0.000 claims description 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
• 108010092160 Dactinomycin Proteins 0.000 claims description 2
• ZINBFGBAIFRYSH-UHFFFAOYSA-N Demethoxyviridin Natural products CC12C(O)C(O)C(=O)c3coc(C(=O)c4c5CCC(=O)c5ccc14)c23 ZINBFGBAIFRYSH-UHFFFAOYSA-N 0.000 claims description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
• 108010029961 Filgrastim Proteins 0.000 claims description 2
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
• 108010069236 Goserelin Proteins 0.000 claims description 2
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
• 102000014150 Interferons Human genes 0.000 claims description 2
• 108010050904 Interferons Proteins 0.000 claims description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
• 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
• 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
• 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
• 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
• 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 2
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 2
• 108010000817 Leuprolide Proteins 0.000 claims description 2
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
• 206010025323 Lymphomas Diseases 0.000 claims description 2
• 229940124640 MK-2206 Drugs 0.000 claims description 2
• ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 claims description 2
• 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 2
• 229930192392 Mitomycin Natural products 0.000 claims description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
• KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 2
• 108010016076 Octreotide Proteins 0.000 claims description 2
• 229930012538 Paclitaxel Natural products 0.000 claims description 2
• 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
• 206010034299 Penile cancer Diseases 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 2
• 201000000331 Testicular germ cell cancer Diseases 0.000 claims description 2
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
• 201000009365 Thymic carcinoma Diseases 0.000 claims description 2
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
• USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 claims description 2
• 229960002736 afatinib dimaleate Drugs 0.000 claims description 2
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 2
• 229960003437 aminoglutethimide Drugs 0.000 claims description 2
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 2
• 229960001220 amsacrine Drugs 0.000 claims description 2
• 229960002932 anastrozole Drugs 0.000 claims description 2
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
• 229960003272 asparaginase Drugs 0.000 claims description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
• 229960003005 axitinib Drugs 0.000 claims description 2
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 2
• 229960000997 bicalutamide Drugs 0.000 claims description 2
• 229960001561 bleomycin Drugs 0.000 claims description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
• 229960001467 bortezomib Drugs 0.000 claims description 2
• CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
• 229960002719 buserelin Drugs 0.000 claims description 2
• 229960002092 busulfan Drugs 0.000 claims description 2
• BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 2
• 229960001573 cabazitaxel Drugs 0.000 claims description 2
• 229960001292 cabozantinib Drugs 0.000 claims description 2
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 2
• 229960004562 carboplatin Drugs 0.000 claims description 2
• 229960002438 carfilzomib Drugs 0.000 claims description 2
• BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
• 108010021331 carfilzomib Proteins 0.000 claims description 2
• 229960005243 carmustine Drugs 0.000 claims description 2
• 229960001602 ceritinib Drugs 0.000 claims description 2
• 201000010881 cervical cancer Diseases 0.000 claims description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
• 229960004630 chlorambucil Drugs 0.000 claims description 2
• 229960003677 chloroquine Drugs 0.000 claims description 2
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
• 229960004316 cisplatin Drugs 0.000 claims description 2
• 229960002286 clodronic acid Drugs 0.000 claims description 2
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 2
• 229960002271 cobimetinib Drugs 0.000 claims description 2
• RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 2
• 229960001338 colchicine Drugs 0.000 claims description 2
• 229960005061 crizotinib Drugs 0.000 claims description 2
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 2
• MKNXBRLZBFVUPV-UHFFFAOYSA-L cyclopenta-1,3-diene;dichlorotitanium Chemical compound Cl[Ti]Cl.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 MKNXBRLZBFVUPV-UHFFFAOYSA-L 0.000 claims description 2
• 229960004397 cyclophosphamide Drugs 0.000 claims description 2
• 229960003843 cyproterone Drugs 0.000 claims description 2
• DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims description 2
• 229960003901 dacarbazine Drugs 0.000 claims description 2
• 229960000640 dactinomycin Drugs 0.000 claims description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
• 229960000975 daunorubicin Drugs 0.000 claims description 2
• SWJBYJJNDIXFSA-KUHUBIRLSA-N demethoxyviridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@]2(C)C3=C1OC=C3C(=O)C[C@H]2O SWJBYJJNDIXFSA-KUHUBIRLSA-N 0.000 claims description 2
• 229940120124 dichloroacetate Drugs 0.000 claims description 2
• JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 2
• NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 claims description 2
• 229960003839 dienestrol Drugs 0.000 claims description 2
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 2
• 229960000452 diethylstilbestrol Drugs 0.000 claims description 2
• 229960003668 docetaxel Drugs 0.000 claims description 2
• 229960001904 epirubicin Drugs 0.000 claims description 2
• 229960003649 eribulin Drugs 0.000 claims description 2
• UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims description 2
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
• 229960001433 erlotinib Drugs 0.000 claims description 2
• 229960005309 estradiol Drugs 0.000 claims description 2
• 229930182833 estradiol Natural products 0.000 claims description 2
• 229960001842 estramustine Drugs 0.000 claims description 2
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 2
• 229960005420 etoposide Drugs 0.000 claims description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
• 229960005167 everolimus Drugs 0.000 claims description 2
• 229960000255 exemestane Drugs 0.000 claims description 2
• 229960004177 filgrastim Drugs 0.000 claims description 2
• AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims description 2
• 229960002011 fludrocortisone Drugs 0.000 claims description 2
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims description 2
• 229960001751 fluoxymesterone Drugs 0.000 claims description 2
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
• 229960002074 flutamide Drugs 0.000 claims description 2
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
• 235000008191 folinic acid Nutrition 0.000 claims description 2
• 239000011672 folinic acid Substances 0.000 claims description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
• 229960002584 gefitinib Drugs 0.000 claims description 2
• 229940045109 genistein Drugs 0.000 claims description 2
• 235000006539 genistein Nutrition 0.000 claims description 2
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 2
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 2
• 229960002913 goserelin Drugs 0.000 claims description 2
• 208000024348 heart neoplasm Diseases 0.000 claims description 2
• 229960000908 idarubicin Drugs 0.000 claims description 2
• 229960001101 ifosfamide Drugs 0.000 claims description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
• 229960002411 imatinib Drugs 0.000 claims description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
• 229940079322 interferon Drugs 0.000 claims description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
• 229960004768 irinotecan Drugs 0.000 claims description 2
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 2
• 229960002014 ixabepilone Drugs 0.000 claims description 2
• 229960004942 lenalidomide Drugs 0.000 claims description 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
• 229960003881 letrozole Drugs 0.000 claims description 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
• 229960001691 leucovorin Drugs 0.000 claims description 2
• 208000032839 leukemia Diseases 0.000 claims description 2
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
• 229960004338 leuprorelin Drugs 0.000 claims description 2
• 229960001614 levamisole Drugs 0.000 claims description 2
• 201000007270 liver cancer Diseases 0.000 claims description 2
• 208000014018 liver neoplasm Diseases 0.000 claims description 2
• 229960002247 lomustine Drugs 0.000 claims description 2
• WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims description 2
• 229960003538 lonidamine Drugs 0.000 claims description 2
• 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
• 229960004961 mechlorethamine Drugs 0.000 claims description 2
• 229960004616 medroxyprogesterone Drugs 0.000 claims description 2
• FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims description 2
• 229960001786 megestrol Drugs 0.000 claims description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
• 229960001924 melphalan Drugs 0.000 claims description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
• 229960001428 mercaptopurine Drugs 0.000 claims description 2
• 229960004635 mesna Drugs 0.000 claims description 2
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
• 229960003105 metformin Drugs 0.000 claims description 2
• 229960000485 methotrexate Drugs 0.000 claims description 2
• PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims description 2
• 229960003775 miltefosine Drugs 0.000 claims description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
• 229960000350 mitotane Drugs 0.000 claims description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
• 229960001156 mitoxantrone Drugs 0.000 claims description 2
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 2
• 229960002653 nilutamide Drugs 0.000 claims description 2
• 229950006344 nocodazole Drugs 0.000 claims description 2
• 229960002700 octreotide Drugs 0.000 claims description 2
• 229960000572 olaparib Drugs 0.000 claims description 2
• FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
• 125000002971 oxazolyl group Chemical group 0.000 claims description 2
• 229960001592 paclitaxel Drugs 0.000 claims description 2
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 2
• 229940046231 pamidronate Drugs 0.000 claims description 2
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
• 229960000639 pazopanib Drugs 0.000 claims description 2
• 229960002340 pentostatin Drugs 0.000 claims description 2
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
• SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 claims description 2
• 229950010632 perifosine Drugs 0.000 claims description 2
• 229960003171 plicamycin Drugs 0.000 claims description 2
• 229960000688 pomalidomide Drugs 0.000 claims description 2
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
• 229960000624 procarbazine Drugs 0.000 claims description 2
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
• 229960004432 raltitrexed Drugs 0.000 claims description 2
• 229960002633 ramucirumab Drugs 0.000 claims description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
• HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 2
• 229950004707 rucaparib Drugs 0.000 claims description 2
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 2
• 229950010746 selumetinib Drugs 0.000 claims description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
• 229960002930 sirolimus Drugs 0.000 claims description 2
• 229960003787 sorafenib Drugs 0.000 claims description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
• 229960001052 streptozocin Drugs 0.000 claims description 2
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
• 229960001796 sunitinib Drugs 0.000 claims description 2
• 229960005314 suramin Drugs 0.000 claims description 2
• 229950004550 talazoparib Drugs 0.000 claims description 2
• 229960001603 tamoxifen Drugs 0.000 claims description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
• 229960004964 temozolomide Drugs 0.000 claims description 2
• 229960000235 temsirolimus Drugs 0.000 claims description 2
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 2
• 229960001278 teniposide Drugs 0.000 claims description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
• 229960003604 testosterone Drugs 0.000 claims description 2
• 229960003433 thalidomide Drugs 0.000 claims description 2
• 125000000335 thiazolyl group Chemical group 0.000 claims description 2
• 125000001544 thienyl group Chemical group 0.000 claims description 2
• 229960001196 thiotepa Drugs 0.000 claims description 2
• 229960003087 tioguanine Drugs 0.000 claims description 2
• 229960000303 topotecan Drugs 0.000 claims description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
• 229960000575 trastuzumab Drugs 0.000 claims description 2
• 229960001727 tretinoin Drugs 0.000 claims description 2
• 125000001425 triazolyl group Chemical group 0.000 claims description 2
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
• JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims description 2
• 229950011257 veliparib Drugs 0.000 claims description 2
• 229960003048 vinblastine Drugs 0.000 claims description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
• 229960004528 vincristine Drugs 0.000 claims description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
• 229960004355 vindesine Drugs 0.000 claims description 2
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 2
• 229960002066 vinorelbine Drugs 0.000 claims description 2
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
• 125000001475 halogen functional group Chemical group 0.000 claims 7
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
• VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 1
• HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
• 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
• 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
• 239000000203 mixture Substances 0.000 description 90
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 62
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 52
• 238000005160 1H NMR spectroscopy Methods 0.000 description 49
• 239000000243 solution Substances 0.000 description 43
• 239000007787 solid Substances 0.000 description 40
• 230000015572 biosynthetic process Effects 0.000 description 35
• 238000003786 synthesis reaction Methods 0.000 description 35
• 235000019439 ethyl acetate Nutrition 0.000 description 34
• 239000000047 product Substances 0.000 description 33
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 28
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 28
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 28
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
• 239000003814 drug Substances 0.000 description 21
• 125000004429 atom Chemical group 0.000 description 20
• 125000001183 hydrocarbyl group Chemical group 0.000 description 20
• 238000011282 treatment Methods 0.000 description 20
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 19
• 239000011541 reaction mixture Substances 0.000 description 19
• 230000001225 therapeutic effect Effects 0.000 description 17
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 16
• 238000009472 formulation Methods 0.000 description 16
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
• 238000002953 preparative HPLC Methods 0.000 description 15
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 14
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
• 229960005305 adenosine Drugs 0.000 description 14
• 239000003795 chemical substances by application Substances 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 230000000694 effects Effects 0.000 description 14
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
• HZQLUIZFUXNFHK-UHFFFAOYSA-N 1-(bromomethyl)-4-phenylbenzene Chemical group C1=CC(CBr)=CC=C1C1=CC=CC=C1 HZQLUIZFUXNFHK-UHFFFAOYSA-N 0.000 description 13
• 125000005842 heteroatom Chemical group 0.000 description 13
• 229910052757 nitrogen Inorganic materials 0.000 description 13
• 239000004480 active ingredient Substances 0.000 description 12
• 239000002775 capsule Substances 0.000 description 12
• 125000005843 halogen group Chemical group 0.000 description 12
• 239000001257 hydrogen Substances 0.000 description 12
• 229910052739 hydrogen Inorganic materials 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
• 239000012044 organic layer Substances 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 238000010898 silica gel chromatography Methods 0.000 description 12
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
• 239000012267 brine Substances 0.000 description 11
• 238000002648 combination therapy Methods 0.000 description 11
• 239000003921 oil Substances 0.000 description 11
• 229920006395 saturated elastomer Polymers 0.000 description 11
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
• 235000019198 oils Nutrition 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• FIARMBRSPSECPP-UHFFFAOYSA-N 2-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC=C1CC#N FIARMBRSPSECPP-UHFFFAOYSA-N 0.000 description 9
• 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 9
• 239000012300 argon atmosphere Substances 0.000 description 9
• 239000003937 drug carrier Substances 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• CAVAMDDXLOUQQV-UHFFFAOYSA-N methyl 2-(1,3-thiazol-4-yl)acetate Chemical compound COC(=O)CC1=CSC=N1 CAVAMDDXLOUQQV-UHFFFAOYSA-N 0.000 description 9
• 239000000843 powder Substances 0.000 description 9
• 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 8
• 239000007832 Na2SO4 Substances 0.000 description 8
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
• 238000010521 absorption reaction Methods 0.000 description 8
• 125000002252 acyl group Chemical group 0.000 description 8
• 150000002148 esters Chemical class 0.000 description 8
• 238000003818 flash chromatography Methods 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 229910052938 sodium sulfate Inorganic materials 0.000 description 8
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 230000008901 benefit Effects 0.000 description 7
• 125000004432 carbon atom Chemical group C* 0.000 description 7
• 125000004122 cyclic group Chemical group 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
• 239000007903 gelatin capsule Substances 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 229940127272 CD73 inhibitor Drugs 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• 239000003963 antioxidant agent Substances 0.000 description 6
• 235000006708 antioxidants Nutrition 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 235000019441 ethanol Nutrition 0.000 description 6
• 235000011187 glycerol Nutrition 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 5
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 125000004423 acyloxy group Chemical group 0.000 description 5
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
• 125000004414 alkyl thio group Chemical group 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• 229910000024 caesium carbonate Inorganic materials 0.000 description 5
• 229910052681 coesite Inorganic materials 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 229910052906 cristobalite Inorganic materials 0.000 description 5
• 125000000392 cycloalkenyl group Chemical group 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 239000008187 granular material Substances 0.000 description 5
• 230000001506 immunosuppresive effect Effects 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 239000006072 paste Substances 0.000 description 5
• 239000003208 petroleum Substances 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• 239000000377 silicon dioxide Substances 0.000 description 5
• 239000007921 spray Substances 0.000 description 5
• 229910052682 stishovite Inorganic materials 0.000 description 5
• 229910052905 tridymite Inorganic materials 0.000 description 5
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 241000416162 Astragalus gummifer Species 0.000 description 4
• ZWPLONWTXXOXLZ-DDFXLWFNSA-N C(O[C@@H]1[C@H](O[C@H]([C@H]1F)N1C2=NC(=NC(=C2N=C1)OCCCC)Cl)CO)(OC(C)(C)C)=O Chemical compound C(O[C@@H]1[C@H](O[C@H]([C@H]1F)N1C2=NC(=NC(=C2N=C1)OCCCC)Cl)CO)(OC(C)(C)C)=O ZWPLONWTXXOXLZ-DDFXLWFNSA-N 0.000 description 4
• UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 4
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
• 229920001615 Tragacanth Polymers 0.000 description 4
• LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 238000011284 combination treatment Methods 0.000 description 4
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 150000002170 ethers Chemical class 0.000 description 4
• YUOAQKWWVPAUBY-UHFFFAOYSA-N ethyl 2-diazo-2-(1,3-thiazol-4-yl)acetate Chemical compound [N+](=[N-])=C(C(=O)OCC)C=1N=CSC=1 YUOAQKWWVPAUBY-UHFFFAOYSA-N 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000008101 lactose Substances 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 239000004006 olive oil Substances 0.000 description 4
• 150000002894 organic compounds Chemical class 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 239000000741 silica gel Substances 0.000 description 4
• 229910002027 silica gel Inorganic materials 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• 235000010487 tragacanth Nutrition 0.000 description 4
• 239000000196 tragacanth Substances 0.000 description 4
• 229940116362 tragacanth Drugs 0.000 description 4
• 239000001993 wax Substances 0.000 description 4
• 239000000080 wetting agent Substances 0.000 description 4
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
• 102000009346 Adenosine receptors Human genes 0.000 description 3
• 108050000203 Adenosine receptors Proteins 0.000 description 3
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
• 229920001817 Agar Polymers 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• OHCBYVYOAVRTCV-PNERYTQFSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)C(=O)OC)C1=CC=CC=C1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)C(=O)OC)C1=CC=CC=C1)O)O OHCBYVYOAVRTCV-PNERYTQFSA-N 0.000 description 3
• KIFJMEHNSUTVEO-ORHJAMKWSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C1=CC=CC=C1)C(=O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C1=CC=CC=C1)C(=O)O)O)O KIFJMEHNSUTVEO-ORHJAMKWSA-N 0.000 description 3
• KIFJMEHNSUTVEO-QFEYAOKZSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C1=CC=CC=C1)C(=O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C1=CC=CC=C1)C(=O)O)O)O KIFJMEHNSUTVEO-QFEYAOKZSA-N 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
• 230000000996 additive effect Effects 0.000 description 3
• 235000010419 agar Nutrition 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
• 229940045799 anthracyclines and related substance Drugs 0.000 description 3
• 235000012216 bentonite Nutrition 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 125000002837 carbocyclic group Chemical group 0.000 description 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 3
• 239000003889 eye drop Substances 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• OWJKEXFJHPORBG-UHFFFAOYSA-N methyl (2E)-2-diazo-2-(1,3-thiazol-4-yl)acetate Chemical compound [N+](=[N-])=C(C(=O)OC)C=1N=CSC=1 OWJKEXFJHPORBG-UHFFFAOYSA-N 0.000 description 3
• RMXGTMRDXKUUDJ-UHFFFAOYSA-N methyl 2-[4-(bromomethyl)phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(CBr)C=C1 RMXGTMRDXKUUDJ-UHFFFAOYSA-N 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 239000002777 nucleoside Substances 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 235000008390 olive oil Nutrition 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 3
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 229960004063 propylene glycol Drugs 0.000 description 3
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 3
• SYBXSZMNKDOUCA-UHFFFAOYSA-J rhodium(2+);tetraacetate Chemical compound [Rh+2].[Rh+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O SYBXSZMNKDOUCA-UHFFFAOYSA-J 0.000 description 3
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 125000000547 substituted alkyl group Chemical group 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• HSVFKFNNMLUVEY-UHFFFAOYSA-N sulfuryl diazide Chemical compound [N-]=[N+]=NS(=O)(=O)N=[N+]=[N-] HSVFKFNNMLUVEY-UHFFFAOYSA-N 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 150000007970 thio esters Chemical class 0.000 description 3
• 238000011200 topical administration Methods 0.000 description 3
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• KLCMUKOPPBLWNT-JVOXNHGTSA-N (2R,3R,4S,5R)-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-[2-chloro-6-(propylamino)purin-9-yl]-4-fluorooxolan-3-ol Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C2=NC(=NC(=C2N=C1)NCCC)Cl KLCMUKOPPBLWNT-JVOXNHGTSA-N 0.000 description 2
• QWBAPFQKJJATRT-UBUPGXEESA-N (2R,3R,4S,5R)-5-(6-butoxy-2-chloropurin-9-yl)-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-fluorooxolan-3-ol Chemical compound C(CCC)OC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)O)F QWBAPFQKJJATRT-UBUPGXEESA-N 0.000 description 2
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• 102000004008 5'-Nucleotidase Human genes 0.000 description 2
• XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
• XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• 241000272517 Anseriformes Species 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• SDRQDFVCQXLEHU-RJDAIHHJSA-N C1(=CC=C(C=C1)CC(C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)CC(C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 SDRQDFVCQXLEHU-RJDAIHHJSA-N 0.000 description 2
• IGTFTBAYFPDEOB-DNJITZFWSA-N C1(=CC=C(C=C1)CC(C(=O)OC)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)CC(C(=O)OC)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 IGTFTBAYFPDEOB-DNJITZFWSA-N 0.000 description 2
• KDUMPDFWQDETHP-SOMWKRHFSA-N C1(=CC=C(C=C1)C[C@@](C(=O)O)(C=1N=C(SC=1)C)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)C[C@@](C(=O)O)(C=1N=C(SC=1)C)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 KDUMPDFWQDETHP-SOMWKRHFSA-N 0.000 description 2
• RNZNUBHMIOHCLE-UUOJPJOSSA-N C1(=CC=C(C=C1)C[C@@](C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)C[C@@](C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 RNZNUBHMIOHCLE-UUOJPJOSSA-N 0.000 description 2
• KDUMPDFWQDETHP-LBGUEWQRSA-N C1(=CC=C(C=C1)C[C@](C(=O)O)(C=1N=C(SC=1)C)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)C[C@](C(=O)O)(C=1N=C(SC=1)C)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 KDUMPDFWQDETHP-LBGUEWQRSA-N 0.000 description 2
• RNZNUBHMIOHCLE-YFKWISHDSA-N C1(=CC=C(C=C1)C[C@](C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)C[C@](C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 RNZNUBHMIOHCLE-YFKWISHDSA-N 0.000 description 2
• 108010080422 CD39 antigen Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• YKQLNPKDDDVHEF-MCOZSMFQSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F)NCCC Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F)NCCC YKQLNPKDDDVHEF-MCOZSMFQSA-N 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
• DULCUDSUACXJJC-UHFFFAOYSA-N Ethyl phenylacetate Chemical compound CCOC(=O)CC1=CC=CC=C1 DULCUDSUACXJJC-UHFFFAOYSA-N 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 241000206672 Gelidium Species 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• BAYQYFRQPMFBKT-OFEMXAOFSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC#N)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC#N)C=1N=CSC=1)O)O BAYQYFRQPMFBKT-OFEMXAOFSA-N 0.000 description 2
• BVMWLDLXCKYNKF-JKQXHPJSSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC(=O)O)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC(=O)O)C=1N=CSC=1)O)O BVMWLDLXCKYNKF-JKQXHPJSSA-N 0.000 description 2
• GBLJLMKPJNQQHL-SOMWKRHFSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)NS(=O)(=O)C)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)NS(=O)(=O)C)C=1N=CSC=1)O)O GBLJLMKPJNQQHL-SOMWKRHFSA-N 0.000 description 2
• DXNXOURHYJQHLB-PREOSKDISA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)OC(F)(F)F)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)OC(F)(F)F)C=1N=CSC=1)O)O DXNXOURHYJQHLB-PREOSKDISA-N 0.000 description 2
• XMYBATSZKIJONB-JKQXHPJSSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1OC)CO)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1OC)CO)C=1N=CSC=1)O)O XMYBATSZKIJONB-JKQXHPJSSA-N 0.000 description 2
• GKLDWJMDACCSAE-ASODLSMBSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=CC=C1)C1=NNC=N1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=CC=C1)C1=NNC=N1)O)O GKLDWJMDACCSAE-ASODLSMBSA-N 0.000 description 2
• PNSOMMPTLZZSOV-GHAKVFGQSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=CC=C1)C=1N=C(SC=1)N)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=CC=C1)C=1N=C(SC=1)N)O)O PNSOMMPTLZZSOV-GHAKVFGQSA-N 0.000 description 2
• DMZRSXSOWJHZLH-ZZPSBVOZSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=CC=C1)C=1N=COC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=CC=C1)C=1N=COC=1)O)O DMZRSXSOWJHZLH-ZZPSBVOZSA-N 0.000 description 2
• QMPYDJMBEYYSCN-QZGKNAEBSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)O QMPYDJMBEYYSCN-QZGKNAEBSA-N 0.000 description 2
• BAYQYFRQPMFBKT-XLMMMINNSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC#N)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC#N)C=1N=CSC=1)O)O BAYQYFRQPMFBKT-XLMMMINNSA-N 0.000 description 2
• BVMWLDLXCKYNKF-PXJASJETSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC(=O)O)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC(=O)O)C=1N=CSC=1)O)O BVMWLDLXCKYNKF-PXJASJETSA-N 0.000 description 2
• GBLJLMKPJNQQHL-LBGUEWQRSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)NS(=O)(=O)C)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)NS(=O)(=O)C)C=1N=CSC=1)O)O GBLJLMKPJNQQHL-LBGUEWQRSA-N 0.000 description 2
• DXNXOURHYJQHLB-BPHXOZSUSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)OC(F)(F)F)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)OC(F)(F)F)C=1N=CSC=1)O)O DXNXOURHYJQHLB-BPHXOZSUSA-N 0.000 description 2
• XMYBATSZKIJONB-PXJASJETSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1OC)CO)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1OC)CO)C=1N=CSC=1)O)O XMYBATSZKIJONB-PXJASJETSA-N 0.000 description 2
• GKLDWJMDACCSAE-BBPZDXPYSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=CC=C1)C1=NNC=N1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=CC=C1)C1=NNC=N1)O)O GKLDWJMDACCSAE-BBPZDXPYSA-N 0.000 description 2
• PNSOMMPTLZZSOV-JSBMJIGBSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=CC=C1)C=1N=C(SC=1)N)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=CC=C1)C=1N=C(SC=1)N)O)O PNSOMMPTLZZSOV-JSBMJIGBSA-N 0.000 description 2
• DMZRSXSOWJHZLH-ITIJPQHDSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=CC=C1)C=1N=COC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=CC=C1)C=1N=COC=1)O)O DMZRSXSOWJHZLH-ITIJPQHDSA-N 0.000 description 2
• ICAWLDBSTMUPEH-IFUCXYJSSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C=1C(=NC=CC=1)OC)C=1N=CSC=1)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C=1C(=NC=CC=1)OC)C=1N=CSC=1)O)F ICAWLDBSTMUPEH-IFUCXYJSSA-N 0.000 description 2
• XPFUNMVDRLCXCK-UEZPCYHUSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C=1C(NC=CC=1)=O)C=1N=CSC=1)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](C(=O)O)(CC1=CC=C(C=C1)C=1C(NC=CC=1)=O)C=1N=CSC=1)O)F XPFUNMVDRLCXCK-UEZPCYHUSA-N 0.000 description 2
• HPHRQPMYBTXZSH-NLMOVWMGSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C(=O)O)C=C1)(C=1N=CSC=1)C(=O)O)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C(=O)O)C=C1)(C=1N=CSC=1)C(=O)O)O)F HPHRQPMYBTXZSH-NLMOVWMGSA-N 0.000 description 2
• PDRCVOMAYNSCJH-DUILOWFOSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)F PDRCVOMAYNSCJH-DUILOWFOSA-N 0.000 description 2
• ICAWLDBSTMUPEH-UXCYTUTESA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C=1C(=NC=CC=1)OC)C=1N=CSC=1)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C=1C(=NC=CC=1)OC)C=1N=CSC=1)O)F ICAWLDBSTMUPEH-UXCYTUTESA-N 0.000 description 2
• XPFUNMVDRLCXCK-JSTVVPCLSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C=1C(NC=CC=1)=O)C=1N=CSC=1)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](C(=O)O)(CC1=CC=C(C=C1)C=1C(NC=CC=1)=O)C=1N=CSC=1)O)F XPFUNMVDRLCXCK-JSTVVPCLSA-N 0.000 description 2
• PDRCVOMAYNSCJH-GIHKOHJZSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)F PDRCVOMAYNSCJH-GIHKOHJZSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241000286209 Phasianidae Species 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• QBSXDGAYNKLHCB-IWQUTFRXSA-N [(2R,3R,4S,5R)-5-(6-butoxy-2-chloropurin-9-yl)-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-fluorooxolan-3-yl] tert-butyl carbonate Chemical compound C(O[C@@H]1[C@H](O[C@H]([C@H]1F)N1C2=NC(=NC(=C2N=C1)OCCCC)Cl)CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)(OC(C)(C)C)=O QBSXDGAYNKLHCB-IWQUTFRXSA-N 0.000 description 2
• NZHIWDLJBIWSJW-FISMMAAMSA-N [Si](C)(C)(C(C)(C)C)O[C@H]1[C@@H](O[C@@H](C1)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OC)N1C2=NC(=NC(=C2N=C1)N)Cl Chemical compound [Si](C)(C)(C(C)(C)C)O[C@H]1[C@@H](O[C@@H](C1)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OC)N1C2=NC(=NC(=C2N=C1)N)Cl NZHIWDLJBIWSJW-FISMMAAMSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001409 amidines Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 125000004103 aminoalkyl group Chemical group 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 235000010290 biphenyl Nutrition 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 125000004452 carbocyclyl group Chemical group 0.000 description 2
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 235000012343 cottonseed oil Nutrition 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 210000003162 effector t lymphocyte Anatomy 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• KDDJRKQGNVBEBO-UHFFFAOYSA-N ethyl 2-[1-(2-trimethylsilylethoxymethyl)-1,2,4-triazol-3-yl]acetate Chemical compound CCOC(=O)CC=1N=CN(COCC[Si](C)(C)C)N=1 KDDJRKQGNVBEBO-UHFFFAOYSA-N 0.000 description 2
• STLJYHFRGWDGQT-UHFFFAOYSA-N ethyl 2-[1-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]acetate Chemical compound C[Si](CCOCN1N=C(C=C1)CC(=O)OCC)(C)C STLJYHFRGWDGQT-UHFFFAOYSA-N 0.000 description 2
• RTVXKEPQWXRYDY-UHFFFAOYSA-N ethyl 4-[4-(bromomethyl)phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=C(CBr)C=C1 RTVXKEPQWXRYDY-UHFFFAOYSA-N 0.000 description 2
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
• 229940093471 ethyl oleate Drugs 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 230000004907 flux Effects 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 150000002334 glycols Chemical class 0.000 description 2
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• IFKONDWPXROQGA-UHFFFAOYSA-N imidazole-1-carbothioic s-acid Chemical compound OC(=S)N1C=CN=C1 IFKONDWPXROQGA-UHFFFAOYSA-N 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 239000002324 mouth wash Substances 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 239000012457 nonaqueous media Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• 229960003347 obinutuzumab Drugs 0.000 description 2
• 150000002895 organic esters Chemical class 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 229960002621 pembrolizumab Drugs 0.000 description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 125000003367 polycyclic group Polymers 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 235000011181 potassium carbonates Nutrition 0.000 description 2
• 150000003138 primary alcohols Chemical class 0.000 description 2
• 230000000135 prohibitive effect Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 108090000623 proteins and genes Proteins 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 108091006082 receptor inhibitors Proteins 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 235000011152 sodium sulphate Nutrition 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 229940032147 starch Drugs 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• LKJQSDRXVWNQNA-OFAGRQRFSA-N tert-butyl [(2R,3R,4S,5R)-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-[2-chloro-6-[(2-methylpropan-2-yl)oxycarbonyl-propylamino]purin-9-yl]-4-fluorooxolan-3-yl] carbonate Chemical compound C(C)(C)(C)OC(=O)O[C@H]1[C@@H]([C@@H](O[C@@H]1CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)N1C2=NC(=NC(=C2N=C1)N(C(OC(C)(C)C)=O)CCC)Cl)F LKJQSDRXVWNQNA-OFAGRQRFSA-N 0.000 description 2
• MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 2
• DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 2
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• NVOLYUXUHWBCRJ-UHFFFAOYSA-N (2-methoxypyridin-3-yl)boronic acid Chemical compound COC1=NC=CC=C1B(O)O NVOLYUXUHWBCRJ-UHFFFAOYSA-N 0.000 description 1
• GLZIGOHMFYRHAO-UHFFFAOYSA-N (2-oxo-1h-pyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=CN=C1O GLZIGOHMFYRHAO-UHFFFAOYSA-N 0.000 description 1
• ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
• YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
• OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 1
• 239000004912 1,5-cyclooctadiene Substances 0.000 description 1
• BQTRMYJYYNQQGK-UHFFFAOYSA-N 1-(bromomethyl)-4-iodobenzene Chemical compound BrCC1=CC=C(I)C=C1 BQTRMYJYYNQQGK-UHFFFAOYSA-N 0.000 description 1
• ZWCYROWFNLFPED-UHFFFAOYSA-N 2-(2-boronophenyl)acetic acid Chemical compound OB(O)C1=CC=CC=C1CC(O)=O ZWCYROWFNLFPED-UHFFFAOYSA-N 0.000 description 1
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
• KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
• HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
• LFFIEVAMVPCZNA-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]benzonitrile Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=C1C#N LFFIEVAMVPCZNA-UHFFFAOYSA-N 0.000 description 1
• WKAVKKUXZAWHDM-UHFFFAOYSA-N 2-acetamidopentanedioic acid;2-(dimethylamino)ethanol Chemical compound CN(C)CCO.CC(=O)NC(C(O)=O)CCC(O)=O WKAVKKUXZAWHDM-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• HQSBCDPYXDGTCL-UHFFFAOYSA-N 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine Chemical compound C1=C(N)C(C)=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2OC=CC=2)=C1 HQSBCDPYXDGTCL-UHFFFAOYSA-N 0.000 description 1
• QSVDFJNXDKTKTJ-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indene Chemical compound C1CCCC2=C1CC=C2 QSVDFJNXDKTKTJ-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• KQROHCSYOGBQGJ-UHFFFAOYSA-N 5-Hydroxytryptophol Chemical compound C1=C(O)C=C2C(CCO)=CNC2=C1 KQROHCSYOGBQGJ-UHFFFAOYSA-N 0.000 description 1
• RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical group C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
• OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
• 235000003276 Apios tuberosa Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• HOLAVDLFJLBNRK-HRWJIFCFSA-N C(=O)(O)C(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C2=NC(=NC(=C2N=C1)NCCC)Cl Chemical compound C(=O)(O)C(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C=1N=CSC=1)OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)N1C2=NC(=NC(=C2N=C1)NCCC)Cl HOLAVDLFJLBNRK-HRWJIFCFSA-N 0.000 description 1
• YJKVNMAAJLIVIX-KPRDSEPWSA-N C(C)(C)(C)OC(=O)N(C1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)OC)C=1N=CSC=1)OC(=O)OC(C)(C)C)F)CCC Chemical compound C(C)(C)(C)OC(=O)N(C1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)OC)C=1N=CSC=1)OC(=O)OC(C)(C)C)F)CCC YJKVNMAAJLIVIX-KPRDSEPWSA-N 0.000 description 1
• FKTVJLGQYIWVJX-DHWQRIIYSA-N C(CCC)OC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F Chemical compound C(CCC)OC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO)O)F FKTVJLGQYIWVJX-DHWQRIIYSA-N 0.000 description 1
• OKGUAAWWDBJHPS-BRRMYOLKSA-N C(CCC)OC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C=1N=CSC=1)O)F Chemical compound C(CCC)OC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C=1N=CSC=1)O)F OKGUAAWWDBJHPS-BRRMYOLKSA-N 0.000 description 1
• JYUUTHPMSHQHIF-VUEMDKHMSA-N C1(=CC=C(C=C1)CC(C(=O)O)(C=1N=C(SC=1)Cl)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)CC(C(=O)O)(C=1N=C(SC=1)Cl)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C2=NC(=NC(=C2N=C1)N)Cl)C1=CC=CC=C1 JYUUTHPMSHQHIF-VUEMDKHMSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 229940123150 Chelating agent Drugs 0.000 description 1
• SHLNTBSZAUWSTG-DQKKFUMGSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C=1N=CSC=1)O)F)NCCC Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C=1N=CSC=1)O)F)NCCC SHLNTBSZAUWSTG-DQKKFUMGSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 102100029723 Ectonucleoside triphosphate diphosphohydrolase 2 Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
• 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• 229930064664 L-arginine Natural products 0.000 description 1
• 235000014852 L-arginine Nutrition 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• AEULVFLPCJOBCE-UHFFFAOYSA-N LSM-3027 Chemical compound C1=CC(OC)=CC=C1CCCN1C(N=C(N)N2C3=NC(=N2)C=2OC=CC=2)=C3C=N1 AEULVFLPCJOBCE-UHFFFAOYSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 101100024551 Mus musculus Msx3 gene Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• VPUJAXYWGPRTRZ-ZHBCTWHMSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H](C[C@H](O1)COC(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C=1N=CSC=1)C(=O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H](C[C@H](O1)COC(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C=1N=CSC=1)C(=O)O)O VPUJAXYWGPRTRZ-ZHBCTWHMSA-N 0.000 description 1
• SVOXYJYMIMVDSF-DTVGWASOSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)C(N(CC)CC)=O)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)C(N(CC)CC)=O)C=1N=CSC=1)O)O SVOXYJYMIMVDSF-DTVGWASOSA-N 0.000 description 1
• JWEXBYJNTLZZNO-IOAAJOQCSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)S(NC)(=O)=O)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)S(NC)(=O)=O)C=1N=CSC=1)O)O JWEXBYJNTLZZNO-IOAAJOQCSA-N 0.000 description 1
• DAWQCABVPLBZQX-QNQWYNDNSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C1=NNC=C1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C1=NNC=C1)O)O DAWQCABVPLBZQX-QNQWYNDNSA-N 0.000 description 1
• CEBBCRRINHNXSF-GFYQZYKNSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C1=NOC(=C1)C)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C1=NOC(=C1)C)O)O CEBBCRRINHNXSF-GFYQZYKNSA-N 0.000 description 1
• CNWRADTURPCYFE-QNQWYNDNSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C=1N=CSC=1)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=CC=C1)C=1N=CSC=1)O)O CNWRADTURPCYFE-QNQWYNDNSA-N 0.000 description 1
• BPYREMFGILQELR-JHZZHVAFSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OC)O)O[Si](C)(C)C(C)(C)C Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OC)O)O[Si](C)(C)C(C)(C)C BPYREMFGILQELR-JHZZHVAFSA-N 0.000 description 1
• ALFMSXZAIKSNRO-KXZBLGGDSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C1=CSC=C1)C(=O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)COC(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C1=CSC=C1)C(=O)O)O)O ALFMSXZAIKSNRO-KXZBLGGDSA-N 0.000 description 1
• QMPYDJMBEYYSCN-GETDZSDQSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)O QMPYDJMBEYYSCN-GETDZSDQSA-N 0.000 description 1
• CDWIVGFLANLQKV-KSVDRFCDSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)C#N)C=1N=CSC=1)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)C#N)C=1N=CSC=1)O)F CDWIVGFLANLQKV-KSVDRFCDSA-N 0.000 description 1
• AFWBPIKMZSGFNY-TUSQIFIHSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC(=O)O)C=1N=CSC=1)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)(CC1=CC=C(C=C1)C1=C(C=CC=C1)CC(=O)O)C=1N=CSC=1)O)F AFWBPIKMZSGFNY-TUSQIFIHSA-N 0.000 description 1
• UCBNRLIPXUNBEP-PDZIOCHISA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)C=1N=CSC=1)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(C(=O)O)C=1N=CSC=1)O)F UCBNRLIPXUNBEP-PDZIOCHISA-N 0.000 description 1
• UJTHXBWAYCWVFE-UMPUYYFFSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(CC1=CC=C(C=C1)C=1C(=CC=CC=1)C(=O)O)(C=1N=CSC=1)C(=O)O)O)F UJTHXBWAYCWVFE-UMPUYYFFSA-N 0.000 description 1
• QCDSYNSTUQAOPL-KKBRPBTJSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(CC=1C=C(C(=O)O)C=CC=1)(C=1N=CSC=1)C(=O)O)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)COC(CC=1C=C(C(=O)O)C=CC=1)(C=1N=CSC=1)C(=O)O)O)F QCDSYNSTUQAOPL-KKBRPBTJSA-N 0.000 description 1
• HPHRQPMYBTXZSH-OVCGBCPVSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C(=O)O)C=C1)(C=1N=CSC=1)C(=O)O)O)F Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](O1)CO[C@](CC1=CC=C(C(=O)O)C=C1)(C=1N=CSC=1)C(=O)O)O)F HPHRQPMYBTXZSH-OVCGBCPVSA-N 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 229910004727 OSO3H Inorganic materials 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• 229910006069 SO3H Inorganic materials 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• WDDFXGQXXQAPHG-VWFIUDSGSA-N [(2r,3r,4s,5r)-3-benzoyloxy-5-(2,6-dichloropurin-9-yl)-4-fluorooxolan-2-yl]methyl benzoate Chemical compound O([C@H]1[C@@H]([C@@H](O[C@@H]1COC(=O)C=1C=CC=CC=1)N1C2=NC(Cl)=NC(Cl)=C2N=C1)F)C(=O)C1=CC=CC=C1 WDDFXGQXXQAPHG-VWFIUDSGSA-N 0.000 description 1
• TULUDWZVHWOWHZ-UHFFFAOYSA-N [2-(diethylcarbamoyl)phenyl]boronic acid Chemical compound CCN(CC)C(=O)C1=CC=CC=C1B(O)O TULUDWZVHWOWHZ-UHFFFAOYSA-N 0.000 description 1
• GOHKJWPMILTEKI-UHFFFAOYSA-N [2-(hydroxymethyl)-6-methoxyphenyl]boronic acid Chemical compound COC1=CC=CC(CO)=C1B(O)O GOHKJWPMILTEKI-UHFFFAOYSA-N 0.000 description 1
• RPRMOEFOTPSWBO-UHFFFAOYSA-N [2-(methanesulfonamido)phenyl]boronic acid Chemical compound CS(=O)(=O)NC1=CC=CC=C1B(O)O RPRMOEFOTPSWBO-UHFFFAOYSA-N 0.000 description 1
• AZXVSPOMIIRTDT-UHFFFAOYSA-N [2-(methylsulfamoyl)phenyl]boronic acid Chemical compound CNS(=O)(=O)C1=CC=CC=C1B(O)O AZXVSPOMIIRTDT-UHFFFAOYSA-N 0.000 description 1
• AIJCNTOYZPKURP-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1OC(F)(F)F AIJCNTOYZPKURP-UHFFFAOYSA-N 0.000 description 1
• 229950005186 abagovomab Drugs 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 125000004442 acylamino group Chemical group 0.000 description 1
• 229950009084 adecatumumab Drugs 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 229950006061 anatumomab mafenatox Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002744 anti-aggregatory effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003556 anti-epileptic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 230000000949 anxiolytic effect Effects 0.000 description 1
• 229950003145 apolizumab Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 210000001742 aqueous humor Anatomy 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• VEJLEEFUXFQSHP-SJKOYZFVSA-N atl-444 Chemical compound C1[C@H](C)CCC[C@@]1(O)C#CC1=NC(N)=C(N=CN2CC#C)C2=N1 VEJLEEFUXFQSHP-SJKOYZFVSA-N 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 210000004082 barrier epithelial cell Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• JBFDZEJAJZJORO-UHFFFAOYSA-N bicyclo[4.1.0]hept-3-ene Chemical compound C1C=CCC2CC21 JBFDZEJAJZJORO-UHFFFAOYSA-N 0.000 description 1
• DCRRIOWFXXDTHV-UHFFFAOYSA-N bicyclo[4.2.0]oct-3-ene Chemical compound C1C=CCC2CCC21 DCRRIOWFXXDTHV-UHFFFAOYSA-N 0.000 description 1
• RPZUBXWEQBPUJR-UHFFFAOYSA-N bicyclo[4.2.0]octane Chemical compound C1CCCC2CCC21 RPZUBXWEQBPUJR-UHFFFAOYSA-N 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• 229960003008 blinatumomab Drugs 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• IUEWAGVJRJORLA-HZPDHXFCSA-N bmn-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 201000008274 breast adenocarcinoma Diseases 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000001273 butane Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 229940095643 calcium hydroxide Drugs 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000005884 carbocyclylalkyl group Chemical group 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 229960000419 catumaxomab Drugs 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 238000011262 co‐therapy Methods 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 238000000315 cryotherapy Methods 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 150000001925 cycloalkenes Chemical group 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 230000001461 cytolytic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960002887 deanol Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 229920006237 degradable polymer Polymers 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
• 125000005131 dialkylammonium group Chemical group 0.000 description 1
• 238000006193 diazotization reaction Methods 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• ZYVZWCILYQDHNU-TTWKNDKESA-L disodium;3-[8-[(e)-2-(3-methoxyphenyl)ethenyl]-7-methyl-2,6-dioxo-1-prop-2-ynylpurin-3-yl]propyl phosphate Chemical compound [Na+].[Na+].COC1=CC=CC(\C=C\C=2N(C=3C(=O)N(CC#C)C(=O)N(CCCOP([O-])([O-])=O)C=3N=2)C)=C1 ZYVZWCILYQDHNU-TTWKNDKESA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• 229950009791 durvalumab Drugs 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229950006370 epacadostat Drugs 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
• 229950009760 epratuzumab Drugs 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000001033 ether group Chemical group 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• UMCBKPOYFXBWBZ-UHFFFAOYSA-N ethyl 2-(1,3-thiazol-4-yl)acetate Chemical compound CCOC(=O)CC1=CSC=N1 UMCBKPOYFXBWBZ-UHFFFAOYSA-N 0.000 description 1
• QWKGDUKXNRZJDH-UHFFFAOYSA-N ethyl 2-(1h-1,2,4-triazol-5-yl)acetate Chemical compound CCOC(=O)CC1=NC=NN1 QWKGDUKXNRZJDH-UHFFFAOYSA-N 0.000 description 1
• MZLKPCAZQWMXFD-UHFFFAOYSA-N ethyl 2-(1h-pyrazol-5-yl)acetate Chemical compound CCOC(=O)CC1=CC=NN1 MZLKPCAZQWMXFD-UHFFFAOYSA-N 0.000 description 1
• SHQNGLYXRFCPGZ-UHFFFAOYSA-N ethyl 2-(2-amino-1,3-thiazol-4-yl)acetate Chemical compound CCOC(=O)CC1=CSC(N)=N1 SHQNGLYXRFCPGZ-UHFFFAOYSA-N 0.000 description 1
• NTEHPRSAVWBTCT-UHFFFAOYSA-N ethyl 2-(2-chloro-1,3-thiazol-4-yl)-2-diazoacetate Chemical compound ClC=1SC=C(N=1)C(C(=O)OCC)=[N+]=[N-] NTEHPRSAVWBTCT-UHFFFAOYSA-N 0.000 description 1
• GNTXHMCYDPZYQU-UHFFFAOYSA-N ethyl 2-(2-chloro-1,3-thiazol-4-yl)acetate Chemical compound CCOC(=O)CC1=CSC(Cl)=N1 GNTXHMCYDPZYQU-UHFFFAOYSA-N 0.000 description 1
• DWSMURKWFWKPBT-UHFFFAOYSA-N ethyl 2-(2-methyl-1,3-thiazol-4-yl)acetate Chemical compound CCOC(=O)CC1=CSC(C)=N1 DWSMURKWFWKPBT-UHFFFAOYSA-N 0.000 description 1
• VINDWLVTWMOTKE-UHFFFAOYSA-N ethyl 2-diazo-3-oxo-3-(1,3-thiazol-4-yl)propanoate Chemical compound [N+](=[N-])=C(C(=O)OCC)C(C=1N=CSC=1)=O VINDWLVTWMOTKE-UHFFFAOYSA-N 0.000 description 1
• FZBNQIWPYCUPAP-UHFFFAOYSA-N ethyl 2-thiophen-3-ylacetate Chemical compound CCOC(=O)CC=1C=CSC=1 FZBNQIWPYCUPAP-UHFFFAOYSA-N 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000003885 eye ointment Substances 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 125000004404 heteroalkyl group Chemical group 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 230000005965 immune activity Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000000899 immune system response Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229950009034 indoximod Drugs 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
• 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
• 238000006713 insertion reaction Methods 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 229950007752 isatuximab Drugs 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
• 229950009028 istradefylline Drugs 0.000 description 1
• 210000000281 joint capsule Anatomy 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229940107698 malachite green Drugs 0.000 description 1
• FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
• CIZBWJVDQHVJSS-UHFFFAOYSA-N methyl 2-(1,3-oxazol-4-yl)acetate Chemical compound COC(=O)CC1=COC=N1 CIZBWJVDQHVJSS-UHFFFAOYSA-N 0.000 description 1
• BFEXHCWYSBOWEK-UHFFFAOYSA-N methyl 2-(5-methyl-1,2-oxazol-3-yl)acetate Chemical compound COC(=O)CC=1C=C(C)ON=1 BFEXHCWYSBOWEK-UHFFFAOYSA-N 0.000 description 1
• YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 1
• NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 210000002200 mouth mucosa Anatomy 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
• 229960003301 nivolumab Drugs 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229950009090 ocaratuzumab Drugs 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960002450 ofatumumab Drugs 0.000 description 1
• 229940042125 oral ointment Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
• 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 235000015320 potassium carbonate Nutrition 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• DTYWJKSSUANMHD-UHFFFAOYSA-N preladenant Chemical compound C1=CC(OCCOC)=CC=C1N1CCN(CCN2C3=C(C4=NC(=NN4C(N)=N3)C=3OC=CC=3)C=N2)CC1 DTYWJKSSUANMHD-UHFFFAOYSA-N 0.000 description 1
• 229950008939 preladenant Drugs 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 229950000106 samalizumab Drugs 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000001624 sedative effect Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940100996 sodium bisulfate Drugs 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229940001482 sodium sulfite Drugs 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
• 238000000967 suction filtration Methods 0.000 description 1
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000003458 sulfonic acid derivatives Chemical group 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-H suramin(6-) Chemical compound [O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)C)C=CC=3)C)=CC=C(S([O-])(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-H 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000004001 thioalkyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 231100000816 toxic dose Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000048 toxicity data Toxicity 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 125000005208 trialkylammonium group Chemical group 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
• 229950003008 vipadenant Drugs 0.000 description 1
• 210000004127 vitreous body Anatomy 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 235000014692 zinc oxide Nutrition 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1